Longeveron Inc. (LGVN) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Follow the formal presentation. Should anyone require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Derek Cole of Investor Relations Advisory Solutions. Thank you. You may begin. Thank you, operator. Good afternoon, everyone, and thank you for joining us today to review Longevron's 2025 first quarter financial results and business updates. After the U.S. markets closed today, we issued a press release with financial results for Q1 2020, which can be found under the investor section of the Longevron website. On the call today are Wael Hashad, Chief Executive Officer, Joshua O'Hare, Co-Founder, Chief Science Officer and Chairman of the Board, Natalia Agafonova, Chief Medical Officer, Lisa Locklear, Chief Financial Officer, and Devin Blass, Chief Technology Officer. As a reminder, during this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press release and risk factors discussed in the company's filings with the Securities and Exchange Commission, which we encourage you to review. Following the company's prepared remarks, we will open the call to questions from covering analysts. With that, let me hand the call over to Dr. Joshua Hare, founder and chairman of the board. Josh? Thank you, Derek. Good afternoon, everyone, and thank you very much for joining us today. We greatly appreciate your interest in Longeviron. We are very pleased to update you on our continued successful progress advancing stem c...